| Mark J Mabee, MD | |
|
1104 W 8th St, Yankton, SD 57078-3306 | |
| (605) 665-7841 | |
| (605) 665-0546 |
| Full Name | Mark J Mabee |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 1104 W 8th St, Yankton, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043211923 | NPI | - | NPPES |
| 5609050 | Medicaid | SD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 3586 (South Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mark J Mabee, MD 1104 W 8th St, Yankton, SD 57078-3306 Ph: (605) 665-7841 | Mark J Mabee, MD 1104 W 8th St, Yankton, SD 57078-3306 Ph: (605) 665-7841 |
News Archive
During colonoscopy screening for bowel cancer and in the four weeks after the procedure, the risk for complications to develop is low.
Responding to a recent study showing that 40% of patients who receive CRT-ICD therapy do not benefit from the device (Sipahi, et al – 6/13/11), Wojciech Zareba, MD, PhD, stated that improving risk stratification of heart failure patients eligible for an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) is essential.
Agência FAPESP – Developed by Biologix, a startup headquartered in São Paulo, Brazil, a sleep apnea home diagnostic and monitoring system based on the Internet of Things can be used for the remote monitoring of individuals with suspected COVID-19 or mild symptoms of the disease.
Health and Human Services Secretary Kathleen Sebelius penned an op-ed last week offering a strong defense of the health law's Independent Payment Advisory Board. Meanwhile, however, the American Medical Association has taken an official position against the panel, and 270 other health care organizations sent a letter to members of Congress expressing their opposition too.
Labopharm Inc. today announced the U.S. Food and Drug Administration (FDA) has approved OLEPTRO(TM) (trazodone hydrochloride) Extended Release Tablets, a novel once-daily formulation of the antidepressant trazodone, for the treatment of major depressive disorder (MDD) in adults. OLEPTRO(TM) utilizes CONTRAMID(R), Labopharm's clinically validated technology that controls the release of active substances within oral medications.
› Verified 1 days ago
Carrissa M Pietz, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1104 W 8th St, Yankton, SD 57078 Phone: 605-665-7841 Fax: 605-665-0546 | |
Elizabeth L Nicholas, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1104 W 8th St, Yankton, SD 57078 Phone: 605-665-7841 Fax: 605-665-0546 | |
Kevin John Post, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 501 Summit St, Yankton, SD 57078 Phone: 605-668-8000 Fax: 605-665-1210 | |
Mckenzie E Hanson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1104 W 8th St, Yankton, SD 57078 Phone: 605-665-7841 | |
John W Brady, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1104 W 8th St, Yankton, SD 57078 Phone: 605-665-7841 Fax: 605-665-0546 | |
David C Krohn, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1104 W 8th St, Yankton, SD 57078 Phone: 605-665-7841 Fax: 605-665-0546 |